What the trial arms establish
The peer-reviewed Phase 2 obesity trial compared placebo with several target-dose and escalation groups over 48 weeks. It supports analysis of dose response and adverse events inside that protocol.
It does not establish that a vial sold by a research vendor is the trial product, nor does it validate self-directed use. Trial participants were screened, monitored, and supplied a controlled formulation.
What remains unresolved
- The final commercial formulation and label have not been approved.
- Research-vendor identity, concentration, sterility, and stability are not guaranteed by the trial publications.
- Cross-trial dose comparisons with approved GLP-1 medicines are not equivalent to head-to-head evidence.
What this evidence review covers
Explain studied Retatrutide dose arms without publishing a consumer dose chart.
- Phase 2 obesity trial arms and escalation design
- Type 2 diabetes trial arms as a separate protocol
- Why milligrams cannot be converted to milliliters without verified concentration
- Why switching, stacking, and washout instructions are not supported
- Link to research and regulatory sources
Source-backed findings
Each claim below is tied to the evidence class that can support it. Commercial listing data and clinical evidence remain separate.
historical trial context
Peer-reviewed trials used predefined arms and controlled escalation schedules.
regulatory/entity boundary
Those schedules do not establish a dose for an unapproved vendor product.
| Evidence class | What the source supports |
|---|---|
| historical trial context | Peer-reviewed trials used predefined arms and controlled escalation schedules. |
| regulatory/entity boundary | Those schedules do not establish a dose for an unapproved vendor product. |
Source-by-source evidence notes
These notes state what each inspected source can support and the boundary that should not be crossed when interpreting it.
Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial
Evidence class: primary randomized phase 2. What it supports: n=338 obesity/overweight trial; receptor description; dose arms; 24- and 48-week weight outcomes; reported adverse events.
What it does not establish: Approved use, long-term benefit-risk, vendor-product equivalence, cross-trial superiority, or a consumer protocol.
Retatrutide in people with type 2 diabetes - randomized phase 2 trial
Evidence class: primary randomized phase 2. What it supports: n=281 type 2 diabetes trial; HbA1c and body-weight endpoints; gastrointestinal-event reporting.
What it does not establish: Outcomes in people without diabetes, an approved indication, or retail-product equivalence.
FDA concerns with unapproved GLP-1 drugs used for weight loss
Evidence class: primary regulatory. What it supports: Retatrutide and cagrilintide are not components of approved drugs, have not been found safe and effective, and cannot be used in compounding under federal law; FDA warnings about false research labels.
What it does not establish: A general claim that every observed listing is unlawful in every jurisdiction.
NCT04881760 phase 2 retatrutide obesity trial
Evidence class: primary trial registry. What it supports: Protocol registration, arms, outcomes, sponsor, and study dates.
What it does not establish: Results not posted in the record or any retail-product claim.
Questions this page answers
What dose did trials study?
Show the published arms with population, starting arm, maintenance arm, duration, and citation-never as a recommendation.
How many syringe units is a trial dose?
The page must not calculate this; units require verified product concentration and would turn trial context into preparation instructions.
What remains unresolved
- No approved label exists to define consumer dosing.
- No verified equivalence between trial supply and listings.
- No switching or combination evidence packet supports instructions.